Publications by authors named "Slesarchuk O"
Article Synopsis
- - The study investigates the effectiveness of post-transplant cyclophosphamide (PTCy) in preventing graft-versus-host disease (GVHD) in pediatric acute leukemia patients who underwent matched allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- - A retrospective analysis of 190 children shows that PTCy-based GVHD prophylaxis led to significantly lower rates of acute and chronic GVHD after transplants from matched unrelated donors (MUD) compared to standard treatments.
- - The findings suggest PTCy is a promising and effective option for GVHD prevention in pediatric patients, particularly in MUD settings, while showing similar efficacy to traditional methods in matched sibling donor (MSD) transplants. *
Article Synopsis
- This analysis reviewed trends in 5185 hematopoietic cell transplantations (HCT) between 1990 and 2022, including 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) transplants.
- There was a significant improvement in event-free survival (EFS) for both autoHCT and alloHCT over time, attributed to a decrease in relapse rates and non-relapse mortality, respectively.
- Specific survival improvements were noted for various conditions, with autoHCT showing better outcomes in Hodgkin's disease and multiple myeloma, while alloHCT advancements were observed mainly in leukemia and lymphomas.
Introduction: Although a number of studies were published on the efficacy of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis, no large studies prospectively evaluated this strategy in related, unrelated, and haploidentical grafts.
Methods: In this study, GVHD prophylaxis for 57 matched bone marrow (MBM) grafts consisted of single-agent PTCy, for 88 matched PBSC grafts (MPBSC) consisted of PTCy, tacrolimus, and mycophenolate mofetil (MMF) 30 mg/kg, and for 55 mismatched grafts (MMGs) consisted of PTCy, tacrolimus and MMF 45 mg/kg.
Results: The study met the primary endpoint to demonstrate equivalent rates of acute GVHD grade II-IV (11%, 17%,19%, P = .
Clinical efficacy of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has been demonstrated in haploidentical and HLA-matched bone marrow but not in unrelated peripheral blood stem cell (PBSC) transplantations. Also, no direct comparisons have been published with current standard of care, combination of antithymocyte globulin (ATG), calcineurin inhibitors, and either methotrexate or mycophenolate mofetil (MMF). Eighty-six adult patients (median age 34 years; range, 18 to 59) with acute myeloblastic and lymphoblastic leukemia underwent unrelated PBSC transplantation with PTCy, tacrolimus, and MMF as GVHD prophylaxis in the single-center trial (clinicaltrial.
View Article and Find Full Text PDFAim: To evaluate the efficacy of donor lymphocyte infusion (DLI) to prevent and treat recurrences in patients after different types of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Subjects And Methods: Data from 118 patients with malignant blood diseases were analyzed. Allo-HSCTs from HLA-matched related donors (n=49), HLA-matched unrelated donors (n=50), partially HLA-matched unrelated donors (n=2), and haploidentical donors (n=24) were performed.
Donor lymphocyte infusions (DLIs) are used for adoptive immunotherapy to prevent or treat relapse and infectious complications after allogeneic hematopoietic stem cell transplantation (HSCT). Unmanipulated DLIs are associated with a risk of graft-versus-host disease (GVHD), probably related to CD8(+) T cell activity. We investigated an automated clinical-scale human-CD4(+)-cell purification method to deplete CD8(+) cells.
View Article and Find Full Text PDF